HIV-related Neuropathy: Difference between revisions

No edit summary
(Added content)
Line 8: Line 8:


== Epidemiology ==
== Epidemiology ==
The estimated pooled frequency of DSN in the pre ART era in Africa was 27% (11–37%)149,152,153. A much lower frequency of 3.9% was reported in a single large study from SA154. The worldwide prevalence during the same period ranged between 20–57%149. A frequency of 50% was reported in HIV2 in one study in West Africa using just one sign+/- symptoms45. In the post ART era in Africa there was a significant increase in frequency of DSN with pooled frequencies of DSN of 52% (36–60%)149,150,152,153,155–159. This increase was attributed to the widespread use of dideoxynucleoside reverse transcriptase inhibitors as a first line ART, in particular stavudine with the neuropathy typically beginning 5–6 months post starting ART153,158,160. In a recent study from SA involving a cohort of patients 2 years after starting ART (60% on stavudine) a slight increase in the frequency of symptomatic DSN from baseline 16% to 18% was reported with a 50% decrease in significant pain161. The rate of symptomatic DSN decreased from 22 to 17% in another study in SA involving 2nd line ART patients with an almost 2 year follow up period, notably the rate of asymptomatic DSN in that study increased from 21% to 29%162. Some studies from West Africa report a decrease in the frequency of DSN at three months post starting ART which may have been too early to observe this side effect of stavudine163,164.
The prevalence of HIV-associated neuropathy varies from 1.73% tot 69.4% among people living with HIV (PLWH).<ref>Yakasai AM, Maharaj S, Danazumi MS. Strength exercise for balance and gait in HIV-associated distal symmetrical polyneuropathy: A randomised controlled trial. Southern African Journal of HIV Medicine. 2021;22(1).</ref> This variation could be attributed to the introduction of anti-retroviral treatment (ART), with its benefits and adverse effects varying with evolving drug-combinations. Diagnostic criteria and geographical region also influence the he prevalence of HIV-associated neuropathy.<ref name=":0">Howlett WP. [https://www.bioline.org.br/pdf?hs19079 Neurological disorders in HIV in Africa: a review.] African health sciences. 2019 Aug 20;19(2):1953-77.</ref> The estimated pooled frequency of DSN in Africa, prior to ART, was 27%. This increased to 52% in the post-ART era, and was mainly attributed to the widespread use of dideoxynucleoside reverse transcriptase inhibitors (like Stavudine).<ref name=":0" />
 
It is however important to note that although the frequency appears to have increased since the introduction of ART, some studies indicate a significant reduction in pain associated with neuropathy - i.e. although patients test positive for neuropathy (based on signs), it is often asymptomatic.<ref name=":0" />


== Clinically Relevant Anatomy<br>  ==
== Clinically Relevant Anatomy<br>  ==
Line 14: Line 16:
add text here relating to '''''clinically relevant''''' anatomy of the condition<br>  
add text here relating to '''''clinically relevant''''' anatomy of the condition<br>  


== Pathological Process ==
== Patholophysiology ==


add text here relating to the mechanism of injury and/or pathology of the condition<br>
Neuropathy typically develops 5-6 months after initiating ART.<ref name=":0" /><br>
 
''DSN: distal axonal neuropathy secondary to activated dorsal root inflammation, likely due to viral proteins.''


ART drugs associated with peripheral neuropathy: Didanosine, Zalcitabine, Stavudine<ref>Hogan C, Wilkins E. Neurological complications in HIV. Clinical Medicine.2011 Dec;11(6):571.</ref>  
ART drugs associated with peripheral neuropathy: Didanosine, Zalcitabine, Stavudine<ref>Hogan C, Wilkins E. Neurological complications in HIV. Clinical Medicine.2011 Dec;11(6):571.</ref>  
Line 22: Line 26:
== Clinical Presentation  ==
== Clinical Presentation  ==


add text here relating to the clinical presentation of the condition
Clinical presentation varies depending on the type of neuropathy (discussed below)


'''Symptoms:'''
== Diagnostic Procedures  ==


* <br>
Based on medical history, clinical examination and laboratory tests


== Diagnostic Procedures  ==
EMG


Based on medical history, clinical examination and laboratory tests
A clinical tool
== Differential Diagnosis  ==
Also see [[Neurological Complications of HIV]] and [[Neuropathies]]


EMG<br>
* [[Myelopathy]] - including Vacuolar Myelopathy and [[Pott's Disease]]
* Opportunistic infections affecting the CNS - TB Meningitis, Neurosyphilis, Toxoplasmosis [[Encephalitis]], Cryptococcal [[Meningitis]]
* Other CNS conditions - [[Stroke]], [[Lymphoma]], Aseptic Meningitis
* [[Vitamin B12 Deficiency|Vitamin B deficiency]] - Vit B12 deficient or excess of vit B6
* Alcoholic neuropathy
* [[Diabetic Neuropathy]]
* Neuropathy related to isolated nerve damage (eg. surgery, compression, traction injury)
* Claudication associated with [[Peripheral Arterial Disease|Peripheral Vascular Disease]]
* Pain and weakness caused by [[Central Sensitisation]]
* Schwannoma
* [[Morton's Neuroma]]


== Outcome Measures  ==
== Outcome Measures  ==  


add links to outcome measures here (see [[Outcome Measures|Outcome Measures Database]])  
add links to outcome measures here (see [[Outcome Measures|Outcome Measures Database]])  


== Types ==
== Types ==
Neuropathy can occur at all stage of HIV, and various types of neuropathy have been documented. The neuropathies present in PLWH include<ref name=":0" />:


=== Distal Sensory Neuropathy (DSN) ===
# '''Distal sensory neuropathy'''
DSN is the most common type of neuropathy in PLWH.<ref name=":0">Howlett WP. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794503/ Neurological disorders in HIV in Africa: a review.] African health sciences. 2019 Aug 20;19(2):1953-77.</ref> It affects the distal extremities (more commonly the feet) and is caused by axonal damage secondary to dorsal root inflammation.  
# '''Inflammatory neuropathies'''
# '''Radiculopathies'''
# '''Mononeuropathies'''
 
=== 1. Distal Sensory Neuropathy (DSN) ===
DSN is the most common type of neuropathy in PLWH.<ref name=":0" />It affects the distal extremities (more commonly the feet) and is caused by axonal damage secondary to dorsal root inflammation. It is more common in the advanced stages of HIV infection (WHO stages 3 and 4). Some patients with DSN (about 25%) do not experiences any sensory symptoms (asymptomatic DSN).<ref name=":0" />


'''Signs and symptoms''' include<ref name=":0" />:
'''Signs and symptoms''' include<ref name=":0" />:


* Burning pain and numbness in the soles of the feet/palms of the hands - this ascends symmetrically
* Burning, stabbing pain and numbness in the soles of the feet/palms of the hands - this ascends symmetrically
* Reduced or absent reflexes
* Sensitivity is most pronounced one the soles and palms
* Reduced or absent ankle reflexes
* Impaired light touch sensation
* Impaired light touch sensation
* Impaired proprioception of the affected region
* Impaired proprioception of the affected region
Line 58: Line 81:
* ART regime that includes Dideoxynucleoside revers transcriptase inhibitors (NRTIs), especially Stavudine
* ART regime that includes Dideoxynucleoside revers transcriptase inhibitors (NRTIs), especially Stavudine


=== Mononeuropathy ===
=== 2. Inflammatory Neuropathies ===
The most common mononeuropathy are:


* '''Facial nerve palsy (Bell's palsy):''' Usually occurs during the early, asymptomatic stages of HIV
=== 3. Radiculopathy ===
* '''Herpes zoster reactivation:'''  One of the earliest signs of HIV, and affects the thoracic and trigeminal nerve
Radiculopathy in less common and when present usually affects the lumbosacral nerve roots, mostly caused by TB or Cytomegalovirus (CMV).


== Management / Interventions  ==
=== 4. Mononeuropathy ===
The most common mononeuropathies are<ref name=":0" />:


* '''HIV infection control -''' early diagnosis and treatment with ARVs
* '''Facial nerve palsy (Bell's palsy):''' Usually occurs during the early, asymptomatic stages of HIV (at seroconversion). It may present as part of an acute inflammatory demyelinating neuropathy, but this is less common.
* '''Drug regime alteration if associated with ARVs -''' Avoiding dideoxynucleoside reverse transcriptase inhibitors
* '''Herpes zoster reactivation:''' One of the earliest signs of HIV, and affects the thoracic and trigeminal nerve. Complications include myelitis and post herpetic neuralgia.
* '''Pain control -''' With neuropathic medication (amitriptyline, gabapentin, pregabalin)
* '''Education -''' On possible other causes of neuropathy (alcohol, diabetes and Vit B6 deficiency secondary to isoniazid)<br>


== Differential Diagnosis ==
== Management / Interventions ==


add text here relating to the differential diagnosis of this condition<br>  
* '''HIV infection control -''' early diagnosis and treatment with ART
* '''Drug regime alteration if associated with ART -''' Avoiding dideoxynucleoside reverse transcriptase inhibitors
* '''Pain control -''' With neuropathic medication (amitriptyline, gabapentin, pregabalin)<ref name=":0" />- see the page on [[Neuropathic Pain]] and [[Pain in People Living with HIV|Pain in PLWH]]
* '''Education -''' On possible other causes of neuropathy (alcohol, diabetes and Vit B6 deficiency secondary to isoniazid)<ref name=":0" />
* '''Treatment of other infections -''' in the case of Herpes reactivation, treatment with acyclovir is indicated<ref name=":0" /> <br>  


== Resources ==
== Resources ==

Revision as of 09:58, 8 December 2023

This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (8/12/2023)
Original Editor - Melissa Coetsee
Top Contributors - Melissa Coetsee, Kim Jackson and Pacifique Dusabeyezu

Introduction[edit | edit source]

Epidemiology[edit | edit source]

The prevalence of HIV-associated neuropathy varies from 1.73% tot 69.4% among people living with HIV (PLWH).[1] This variation could be attributed to the introduction of anti-retroviral treatment (ART), with its benefits and adverse effects varying with evolving drug-combinations. Diagnostic criteria and geographical region also influence the he prevalence of HIV-associated neuropathy.[2] The estimated pooled frequency of DSN in Africa, prior to ART, was 27%. This increased to 52% in the post-ART era, and was mainly attributed to the widespread use of dideoxynucleoside reverse transcriptase inhibitors (like Stavudine).[2]

It is however important to note that although the frequency appears to have increased since the introduction of ART, some studies indicate a significant reduction in pain associated with neuropathy - i.e. although patients test positive for neuropathy (based on signs), it is often asymptomatic.[2]

Clinically Relevant Anatomy
[edit | edit source]

add text here relating to clinically relevant anatomy of the condition

Patholophysiology[edit | edit source]

Neuropathy typically develops 5-6 months after initiating ART.[2]

DSN: distal axonal neuropathy secondary to activated dorsal root inflammation, likely due to viral proteins.

ART drugs associated with peripheral neuropathy: Didanosine, Zalcitabine, Stavudine[3]

Clinical Presentation[edit | edit source]

Clinical presentation varies depending on the type of neuropathy (discussed below)

Diagnostic Procedures[edit | edit source]

Based on medical history, clinical examination and laboratory tests

EMG

A clinical tool

Differential Diagnosis[edit | edit source]

Also see Neurological Complications of HIV and Neuropathies

Outcome Measures[edit | edit source]

add links to outcome measures here (see Outcome Measures Database)

Types[edit | edit source]

Neuropathy can occur at all stage of HIV, and various types of neuropathy have been documented. The neuropathies present in PLWH include[2]:

  1. Distal sensory neuropathy
  2. Inflammatory neuropathies
  3. Radiculopathies
  4. Mononeuropathies

1. Distal Sensory Neuropathy (DSN)[edit | edit source]

DSN is the most common type of neuropathy in PLWH.[2]It affects the distal extremities (more commonly the feet) and is caused by axonal damage secondary to dorsal root inflammation. It is more common in the advanced stages of HIV infection (WHO stages 3 and 4). Some patients with DSN (about 25%) do not experiences any sensory symptoms (asymptomatic DSN).[2]

Signs and symptoms include[2]:

  • Burning, stabbing pain and numbness in the soles of the feet/palms of the hands - this ascends symmetrically
  • Sensitivity is most pronounced one the soles and palms
  • Reduced or absent ankle reflexes
  • Impaired light touch sensation
  • Impaired proprioception of the affected region

Risk factors for developing DSN[2]:

  • Advanced HIV disease
  • Lower CD4 count and high viral load
  • A history of prior TB or alcohol abuse
  • ART regime that includes Dideoxynucleoside revers transcriptase inhibitors (NRTIs), especially Stavudine

2. Inflammatory Neuropathies[edit | edit source]

3. Radiculopathy[edit | edit source]

Radiculopathy in less common and when present usually affects the lumbosacral nerve roots, mostly caused by TB or Cytomegalovirus (CMV).

4. Mononeuropathy[edit | edit source]

The most common mononeuropathies are[2]:

  • Facial nerve palsy (Bell's palsy): Usually occurs during the early, asymptomatic stages of HIV (at seroconversion). It may present as part of an acute inflammatory demyelinating neuropathy, but this is less common.
  • Herpes zoster reactivation: One of the earliest signs of HIV, and affects the thoracic and trigeminal nerve. Complications include myelitis and post herpetic neuralgia.

Management / Interventions[edit | edit source]

  • HIV infection control - early diagnosis and treatment with ART
  • Drug regime alteration if associated with ART - Avoiding dideoxynucleoside reverse transcriptase inhibitors
  • Pain control - With neuropathic medication (amitriptyline, gabapentin, pregabalin)[2]- see the page on Neuropathic Pain and Pain in PLWH
  • Education - On possible other causes of neuropathy (alcohol, diabetes and Vit B6 deficiency secondary to isoniazid)[2]
  • Treatment of other infections - in the case of Herpes reactivation, treatment with acyclovir is indicated[2]

Resources[edit | edit source]

add appropriate resources here

References[edit | edit source]

  1. Yakasai AM, Maharaj S, Danazumi MS. Strength exercise for balance and gait in HIV-associated distal symmetrical polyneuropathy: A randomised controlled trial. Southern African Journal of HIV Medicine. 2021;22(1).
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 Howlett WP. Neurological disorders in HIV in Africa: a review. African health sciences. 2019 Aug 20;19(2):1953-77.
  3. Hogan C, Wilkins E. Neurological complications in HIV. Clinical Medicine.2011 Dec;11(6):571.